Detail akcie ProQR Therapeutics online

Business Summary: ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Financial Summary: BRIEF: For the nine months ended 30 September 2024, ProQR Therapeutics NV revenues increased from EUR3.3M to EUR15.1M. Net loss decreased 18% to EUR18.5M. Revenues reflect RNA based Therapeutics segment increase from EUR2.6M to EUR15.1M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR0.28 to -EUR0.23.